US4959358A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug administration
Assignee: The Brigham and Women's Hospital Inc
•
Filing: 1988-05-23
•
Granted: 1990-09-25
•
Expires: 2008-05-23
Abstract
Abstract Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of the human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.
Inventors
- 👤 Martin C. Carey
- 👤 Alan C. Moses
- 👤 Jeffrey S. Flier
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 02:12
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/28; A61K31/00; A61K31/13; A61K31/135; A61K31/137; A61K31/33; A61K31/395; A61K31/54; A61K31/542; A61K31/545; A61K45/00; A61K45/06; A61K9/00; A61K9/0012; A61K9/0014; A61K9/0043; A61K9/0048
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
197 words
In a method of administering a drug which comprises applying to a human or animal mucosal surface for absorption across said mucosal surface as an active ingredient, a biologically-effective amount of a drug specific for the disorder or condition the improvement comprising applying the drug to the mucosal surface in admixture with a biocompatible, water-soluble, fusidic acid derivative having the formula: ##STR3## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water-soluble within a range of about pH 2 to about pH 12; E and G each represent OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents OAc or H; and Q, V and X each represent H or OH, said steroid containing from two to three polar functions, exclusive of the function represented by D, which biocompatible, water-soluble, fusidic acid derivative acts as an adjuvant being capable of increasing drug permeability of a human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of said surface to said drug.
Claim 2
Dependent Claim
197 words
In a method of administering a drug which comprises applying to a human or animal mucosal surface for absorption across said mucosal surface as an active ingredient, a biologically-effective amount of a drug specific for the disorder or condition the improvement comprising applying the drug to the mucosal surface in admixture with a biocompatible, water-soluble, fusidic acid derivative having the formula: ##STR3## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below about 600 daltons which renders an effective amount of said steroid water-soluble within a range of about pH 2 to about pH 12; E and G each represent OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents OAc or H; and Q, V and X each represent H or OH, said steroid containing from two to three polar functions, exclusive of the function represented by D, which biocompatible, water-soluble, fusidic acid derivative acts as an adjuvant being capable of increasing drug permeability of a human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of said surface to said drug.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein the mucosal surface is a nasal mucosal surface.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein the mucosal surface is a conjunctival surface.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein the mucosal surface is an oropharyngeal, nasopharyngeal or respiratory tract surface.
Claim 6
Dependent Claim
16 words
The method of claim 1 wherein the mucosal surface is a vaginal, cervical or endometrial surface.
Claim 7
Dependent Claim
17 words
The method of claim 1 wherein the mucosal surface is a rectal, colonic, gastric or intestinal surface.
Claim 8
Dependent Claim
16 words
The method of claim 1 wherein the mucosal surface is a urethral or urinary bladder surface.
Claim 9
Dependent Claim
16 words
The method of claim 1 wherein the human or animal body surface is an epithelial surface.
Claim 10
Dependent Claim
20 words
The method of claim 1 wherein the human or animal body surface is an ear canal or tympanic membrane surface.
Claim 11
Dependent Claim
20 words
The method of claim 1 wherein the composition is applied in the form of a nasal spray or nose drops.
Claim 12
Dependent Claim
16 words
The method of claim 1 wherein the composition is applied in the form of eye drops.
Claim 13
Dependent Claim
16 words
The method of claim 1 wherein the composition is applied in the form of a suppository.
Claim 14
Dependent Claim
20 words
The method of claim 1 wherein the composition is applied in the form of a spray, salve, ointment or cream.
Claim 15
Dependent Claim
10 words
The method of claim 1 wherein the drug is epinephrine.
Claim 16
Dependent Claim
25 words
The method of claim 14 wherein the epinephrine is applied to a nasal mucosal surface in the form of a nasal spray or nose drops.
Claim 17
Dependent Claim
17 words
The method of claim 1 wherein the composition is applied in a long term release dosage form.
Claim 18
Dependent Claim
19 words
The method of claim 16 wherein the long term release dosage form is a slow, continuous or intermittent form.
Claim 19
Dependent Claim
37 words
The method of claim 16 wherein the long term release dosage form is selected from the group consisting of a polymer form, a microcapsule form, a microsphere form, an osmotic diffusion device or a membrane release device.
Claim 20
Dependent Claim
11 words
The method of claim 1 wherein the drug is an antibiotic.
References Cited (Backward Citations)
US3867413A
Cited
US4060606A
Cited
US4100276A
Cited
US4119717A
Cited
US4548922A
Cited
US4746508A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-24 | 1994-03-26 | 1994-09-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-24 | 1998-03-26 | 1998-09-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-24 | 2002-03-26 | 2002-09-25 | $7700.00 | Window Closed / Lapsed |